liquidbiopsyinfo.com

If you are an oncologist trying to determine whether MRD testing could guide treatment decisions for a specific patient — where do you turn? If you are a patient who has heard about liquid biopsy and wants to understand what the evidence says for your type of cancer — how do you find reliable, current answers?

Today, this information is scattered across hundreds of publications, conference abstracts, and clinical trial databases. No single resource pulls it together in a way that is accessible, structured, and up to date. This is the gap we set out to close.

Who we are

We are LIQOMICS — a European pioneer in the detection of circulating tumor DNA (ctDNA). For years, our work has focused on making liquid biopsy diagnostics available to every patient who can benefit from them. But access to testing alone is not enough. Patients and oncologists also need access to the evidence that supports informed, confident decisions.

That is why we created liquidbiopsyinfo.com.

What this platform offers

liquidbiopsyinfo.com provides structured, evidence-based information on liquid biopsy applications — covering minimal residual disease (MRD) detection and molecular profiling across more than 20 cancer types. The content is grounded in peer-reviewed literature and clinical trial data, organized to help you quickly find what is relevant to your specific situation.

A word on how we work — and our limits

We believe in transparency. The volume of data in this field is vast and growing fast. To keep this resource current, we use AI to structure, synthesize, and update the information presented here. This allows us to move at the speed the science demands — but it also means we must be honest about the boundaries.

The information on liquidbiopsyinfo.com is for educational purposes only and should not be used as a basis for medical decisions. Always consult qualified healthcare professionals for clinical advice and treatment planning.

We know that AI-curated content requires human oversight to meet the standards that patients and clinicians deserve. That is why we are committed to building a continuous review process — and why we are actively seeking collaboration with clinical experts, researchers, and medical professionals who share our goal of making this resource as accurate and trustworthy as possible.

An invitation

We see ourselves not as an authority handing down information, but as an ally — working alongside oncologists and patients to make sense of a rapidly evolving field. We move fast because the need is urgent. We are transparent because trust must be earned. And we are reaching out because the best outcomes come from collaboration.

If you are a clinician, researcher, or expert in liquid biopsy diagnostics and would like to contribute to our review process, we would welcome the conversation.

Contact us →

— The LIQOMICS Team